Recommended Free Tools
Umoja Biopharma said it closed a $100 million Series C financing on January 14, 2025. The Seattle-based company said it would use the proceeds to advance its in vivo CAR T pipeline, including its lead CD22 program, UB-VV400, through oncology and autoimmune clinical studies. The financing supports development; it is not evidence that a candidate works or has been approved.
What Umoja said the $100 million will fund
In its January 14, 2025 financing announcement, Umoja said the money would support development of its in vivo CAR T pipeline, including UB-VV400, across oncology and autoimmune clinical studies. The company did not disclose a candidate-by-candidate budget or more specific allocation in that announcement.
Double Point Ventures and DCVC Bio co-led the round. Umoja also named these participants: ARK Invest, Cormorant Asset Management, MPM Capital, Qiming Venture Partners USA, RTW Investments, Alexandria Venture Investments, SoftBank Vision Fund 2, CaaS Capital, Emerson Collective Investments managed by Yosemite, K2 HealthVentures, Myeloma Investment Fund, and the University of Minnesota Endowment.
What Umoja’s in vivo CAR T approach means
CAR T therapy uses a patient’s T cells, a type of immune cell, engineered to recognize a target. In the conventional ex vivo approach, cells are collected, modified outside the body, and then returned to the patient. Umoja describes its VivoVec platform as a way to deliver genetic instructions in the patient so CAR T cells can be generated there. The company says its candidates are intended for on-demand administration, avoiding the multi-week manufacturing step associated with ex vivo CAR T therapies. These are design aims described by Umoja, not established comparative clinical results.
Quick wins for a faster PC:
Clear out junk files and repair common Windows errorsFree Scan →Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →Repair Windows errors before they cause bigger problemsFix Now →#1 Best Overall
Umoja’s company overview describes a clinical-stage biotechnology business focused on cell therapies for oncology, with possible applications in other conditions. Its financing release identifies a lentiviral vector development and manufacturing facility in Louisville, Colorado; GeekWire’s January 14, 2025 report also described Seattle headquarters and Colorado manufacturing operations.
What the financing does—and does not—show
The $100 million figure is the announced financing amount. Umoja did not disclose a company valuation in the financing release, and the amount is not a measure of clinical progress. A funding round can provide capital to pursue development milestones; it does not establish that a therapy is safe, effective, or commercially available.
Rank #2
- Cancer Immunotherapy Principles and Practice
- ABIS BOOK
- Demos Medical Publishing
In the release, co-founder and CEO Andrew Scharenberg characterized the company’s aim as developing in vivo CAR T cell-generating therapies in the hope of increasing effectiveness, reducing barriers, and expanding access. That statement describes the company’s ambition, not independently demonstrated outcomes or confirmation that Umoja will be first to achieve them.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.Regulatory updates since the funding announcement
Umoja’s newsroom reports that the FDA cleared the UB-VV400 IND application on July 16, 2026, and granted UB-VV111 Fast Track designation on September 30, 2025. These are regulatory milestones reported by the company. IND clearance allows a study to proceed under the applicable regulatory framework; Fast Track is a development designation. Neither means a therapy is approved or that clinical benefit has been demonstrated.
Quick Recap
Rank #3
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
